Core Insights - Illumina Inc. will collaborate with several global pharmaceutical companies to develop companion diagnostics for the KRAS biomarker [1] Group 1: Company Developments - Illumina's partnership aims to enhance the capabilities of the TruSight™ Oncology Comprehensive genomic profiling test [1]